The Asia Pacific Sterility Testing Market should witness market growth of 10.8% CAGR during the forecast period (2023-2029).
The sterility testing market is driven by an increase in chronic diseases and a rise in healthcare awareness. Chronic diseases, like cancer, heart disease, and diabetes, are ailments that persist for a year or longer and call for regular medical attention. Chronic diseases are becoming more prevalent due to changes in human lifestyle, including poor nutrition, physical inactivity, rising intake of fast food, and excessive alcohol drinking. In the pharmaceutical & biotechnology sectors, sterility testing is carried out at every production stage to lessen the risk of product contamination. Thus, the growth of this end-use industry in the approaching years will dramatically raise the use of sterility testing.
In the near future, the sterility testing market is expected to expand due to the rising demand for sterilized products and their exclusivity in several industries. The growth media used during the sterility testing must be correctly prepared and tested for microbial growth to be as effective as possible. Throughout the projected period, the sterility testing market is anticipated to develop as a result of rising technological improvements.
The Chinese government is expanding its spending on research and development and healthcare. Therefore, China offers great possibilities for multinational and domestic pharmaceutical companies to collaborate. Due to an aging population, increased per capita healthcare spending, and growing health awareness, China's pharmaceutical sector is expanding. As opposed to this, biopharmaceutical sales account for about 30% of total pharmaceutical sales worldwide and about 15% of drug sales in Japan. The regional sterility testing market will expand due to the expanding pharmaceutical sector in the regional countries.
The China market dominated the Asia Pacific Sterility Testing Market by Country in 2022; thereby, achieving a market value of $130.4 million by 2029. The Japan market is registering a CAGR of 10.1% during (2023-2029). Additionally, The India market would showcase a CAGR of 11.4% during (2023-2029).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Test Type, the market is segmented into Membrane Filtration, Direct Inoculation and Others. Based on Application, the market is segmented into Pharmaceuticals & Biologicals, Medical Devices and Others. Based on End-user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Charles River Laboratories International, Inc., SGS S.A., Merck KGaA, BioMérieux S.A., WuXi AppTec Co., Ltd., Sartorius AG, Samsung Biologics Co., Ltd. (Samsung Group), Nelson Laboratories, LLC (Sotera Health Company) and Pacific Biolabs, Inc.
The sterility testing market is driven by an increase in chronic diseases and a rise in healthcare awareness. Chronic diseases, like cancer, heart disease, and diabetes, are ailments that persist for a year or longer and call for regular medical attention. Chronic diseases are becoming more prevalent due to changes in human lifestyle, including poor nutrition, physical inactivity, rising intake of fast food, and excessive alcohol drinking. In the pharmaceutical & biotechnology sectors, sterility testing is carried out at every production stage to lessen the risk of product contamination. Thus, the growth of this end-use industry in the approaching years will dramatically raise the use of sterility testing.
In the near future, the sterility testing market is expected to expand due to the rising demand for sterilized products and their exclusivity in several industries. The growth media used during the sterility testing must be correctly prepared and tested for microbial growth to be as effective as possible. Throughout the projected period, the sterility testing market is anticipated to develop as a result of rising technological improvements.
The Chinese government is expanding its spending on research and development and healthcare. Therefore, China offers great possibilities for multinational and domestic pharmaceutical companies to collaborate. Due to an aging population, increased per capita healthcare spending, and growing health awareness, China's pharmaceutical sector is expanding. As opposed to this, biopharmaceutical sales account for about 30% of total pharmaceutical sales worldwide and about 15% of drug sales in Japan. The regional sterility testing market will expand due to the expanding pharmaceutical sector in the regional countries.
The China market dominated the Asia Pacific Sterility Testing Market by Country in 2022; thereby, achieving a market value of $130.4 million by 2029. The Japan market is registering a CAGR of 10.1% during (2023-2029). Additionally, The India market would showcase a CAGR of 11.4% during (2023-2029).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Test Type, the market is segmented into Membrane Filtration, Direct Inoculation and Others. Based on Application, the market is segmented into Pharmaceuticals & Biologicals, Medical Devices and Others. Based on End-user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Charles River Laboratories International, Inc., SGS S.A., Merck KGaA, BioMérieux S.A., WuXi AppTec Co., Ltd., Sartorius AG, Samsung Biologics Co., Ltd. (Samsung Group), Nelson Laboratories, LLC (Sotera Health Company) and Pacific Biolabs, Inc.
Scope of the Study
By Product
- Kits & Reagents
- Instruments
- Services
By Test Type
- Membrane Filtration
- Direct Inoculation
- Others
By Application
- Pharmaceuticals & Biologicals
- Medical Devices
- Others
By End-user
- Pharmaceutical Companies
- Biotechnology Companies
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- Charles River Laboratories International, Inc.
- SGS S.A.
- Merck KGaA
- BioMérieux S.A.
- WuXi AppTec Co., Ltd.
- Sartorius AG
- Samsung Biologics Co., Ltd. (Samsung Group)
- Nelson Laboratories, LLC (Sotera Health Company)
- Pacific Biolabs, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Sterility Testing Market by Product
Chapter 4. Asia Pacific Sterility Testing Market by Test Type
Chapter 5. Asia Pacific Sterility Testing Market by Application
Chapter 6. Asia Pacific Sterility Testing Market by End User
Chapter 7. Asia Pacific Sterility Testing Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Charles River Laboratories International, Inc.
- SGS S.A.
- Merck KGaA
- BioMérieux S.A.
- WuXi AppTec Co., Ltd.
- Sartorius AG
- Samsung Biologics Co., Ltd. (Samsung Group)
- Nelson Laboratories, LLC (Sotera Health Company)
- Pacific Biolabs, Inc.
Methodology
LOADING...
